Sai Life Sciences

Sai Life Sciences Limited - IPO

MAINBOARD

Sai Life Sciences Stock Price

755.00 A2ZIPO
-0.40 (-0.05%)
16 May, 2025 12:14:54 PM | All Prices in ₹
Previous Close
755.40
Open
758.00
High
760.75
Low
741.05
Exchange
NSE
52 week High (26 Dec 2024)
808.80
52 week Low (09 Apr 2025)
636.10
Upper Price Band
906.45
Lower Price Band
604.35
Price Band
20.00%
753.30 A2ZIPO
-2.00 (-0.26%)
16 May, 2025 04:01:00 PM | All Prices in ₹
Previous Close
755.30
Open
759.95
High
760.20
Low
741.10
Exchange
BSE
52 week High
808.20
52 week Low
635.30
Upper Price Band
906.35
Lower Price Band
604.25
Price Band
20.00%

Sai Life Sciences IPO Details

Open Date
11 Dec 2024
Close Date
13 Dec 2024
Listing Date
18 Dec 2024
Issue Price
₹522 - ₹549
Face Value
₹1 per share
Lot Size
27
GMP
₹72 (13.1%)
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
190685340
Share holding post issue
-
Total Issue Size
5,54,21,123 shares (aggregating up to ₹3042.62 Cr.)
Fresh Issue
1,73,04,189 shares (aggregating up to ₹950 Cr)
Offer for Sale
3,81,16,934 shares (aggregating up to ₹2092.62 Cr)

Sai Life Sciences IPO Subscription

Sai Life Sciences IPO Application Wise Breakup (Approx)

Sai Life Sciences IPO Dates

  • 11 Dec 2024
    Opening dateOPD
  • 13 Dec 2024
    Closing dateCOD
  • 16 Dec 2024
    Basis of AllotmentBOA
  • 17 Dec 2024
    Initiation of RefundsIOR
  • 17 Dec 2024
    Credit of SharesCOS
  • 18 Dec 2024
    Listing dateLID

Sai Life Sciences IPO Lot Size

ApplicationLotsSharesAmount
Retain Minimum127₹14,823
Retain Maximum13351₹192,699
SHNI Minimum14378₹207,522
SHNI Maximum671809₹993,141
BHNI Minimum681836₹1,007,964

Sai Life Sciences IPO Reservation

Promoter Holding

Pre Issue:41.82%
Post Issue:35.24%
Promoter Names:
Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners, Tulip Partners

Sai Life Sciences IPO Valuations

ROE:11.79%
ROCE:15.96%
RoNW:8.13%
PAT Margin (%):5.65

Sai Life Sciences Limited Financial Information

Sai Life Sciences Limited's revenue increased by 20% and profit after tax (PAT) rose by 729% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended30 Sep 202431 Mar 202431 Mar 202331 Mar 2022
Assets2,476.782,275.142,186.652,164.23
Revenue693.351,494.271,245.11897.74
Profit After Tax28.0182.819.996.23
Net Worth1,044.75974.34887.29877.76
Reserves and Surplus855.69953.99867.43859.17
Total Borrowing764.49710.16699.23751.32
Amount in ₹ Crore

About Sai Life Sciences IPO

Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.

In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.

The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.

The company has the following service offerings.

  • Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
  • CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics

As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.

As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.

Competitive Strength:

  1. As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing.
  2. CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics.
  3. CDMO platform with a diverse mix of commercial and under-development molecules

Strength Of Sai Life Sciences IPO

1. One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing.

2. CDMO platform with a diverse mix of commercial and under-development molecules.

3. Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services.

4. Long-standing relationship with a diverse base of existing and new customers.

5. Modern R&D infrastructure with a differentiated delivery model and strong regulatory track-record.

6. Experienced management team and Board supported by a qualified scientific talent pool.

7. Strategic business investments with improving profitability metrics.

Risk Of Sai Life Sciences IPO

1. Its financial performance depends on the company's ability to secure business from biotechnology and pharmaceutical customers and consequently its may be subject to risks, uncertainties and trends that affect the company customers in these industries over which the company has no control.

2. Its business may be adversely affected by a failures to develop or manufacture commercially viable drugs, including for reasons that are not within the company control.

3. The company may not be able to continue to serve its customers if the company fails to meet their standards in audits and inspections and this could significantly harm its reputation and result in the termination of ongoing projects by its customers.

4. The company depends on its research and development activities generally for the company future growth and its inability to achieve the desired outcomes in the company research and development activities may result in customers opting to discontinue their partnerships with it.

5. The company is subject to extensive government regulation, and if the company fails to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company's business, results of operations and cash flows may be adversely affected.

6. Manufacturing interruptions or delays could affect its ability to meet customer demand and lead to higher costs.

7. The company is subject to risks associated with conducting business internationally, and any operational delays and/or additional financial burdens may affect its business and results of operations.

8. The potential loss of major customers or any of its large contracts could materially and adversely affect the company's business, financial condition and results of operations.

9. The company conduct animal testing, which can result in adverse publicity liability and other issues, including potential disruption to its facilities as a result of protests against animal testing.

10. There have been instances in the past where the company has not made certain regulatory filings with the RoC or there were certain instances of discrepancies in relation to certain statutory filings and corporate records of the Company. Its cannot assure you that regulatory proceedings or actions will not be initiated against it in the future and the company will not be subject to any penalty imposed by the competent regulatory authority in this regard.

Objectives Sai Life Sciences IPO

  1. Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
  2. General corporate purposes

Company Contact Details

Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal,
Malkajgiri District, Hyderabad-500078
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/

Registrar Contact Details

Name: Kfin Technologies Limited
Phone: +91-40-67162222

Lead Mangers

  1. Kotak Mahindra Capital Company Limited

  2. Iifl Securities Ltd

  3. Jefferies India Private Limited

  4. Morgan Stanley India Company Pvt Ltd

Comments